fda ban tirzepatide 🚨 Moves to Permanently Shut Down Compounded GLP-1s The FDA is taking steps to eliminate large-scale compounding of GLP-1 medications like semaglutide and tirzepatide, signaling a major shift in how these fda warning letters compounded tirzepatide

Detection of Post-Translational Modifications (PTMs) PTMs in semaglutide are often subtle and difficult to detect

Proper compounded semaglutide storage also affects the degradation profile

Additional prespecified AEs across all weight groups and doses included skin infections (6% for Dupixent every four weeks, 8% for Dupixent every two weeks, and 13% for TCS alone), which is noteworthy because patients with atopic dermatitis have an increased risk of skin infections

Other glycogen storage causes include Tarui disease due to phosphofructokinase deficiency ( PFKM gene), phosphorylase kinase deficiency ( PHKA1 , PHKB genes), beta-enolase ( ENO3 gene), phosphoglycerate mutase ( PGAM2 gene), phosphoglycerate kinase 1 ( PGK1 gene), aldolase A ( ALDOA gene), lactate dehydrogenase ( LDHA gene), and phosphoglucomutase ( PGM1 gene) deficiencies (28

During these plateaus, it can be frustrating when you are not seeing progress on the scale